Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) is a publicly traded Healthcare sector company. As of May 20, 2026, SNY trades at $44.50 with a market cap of $104.32B and a P/E ratio of 0.00. SNY moved +2.58% today. Year to date, SNY is -5.98%; over the trailing twelve months it is -15.54%. Its 52-week range spans $42.33 to $60.12. Analyst consensus is neutral with an average price target of $53.00. Rallies surfaces SNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sanofi/Regeneron COPD Trial Shows 27% Benefit in AERIFY-1 but Fails in AERIFY-2: Sanofi and Regeneron’s itepekimab delivered 27.1% and 20.5% reductions in moderate-severe COPD exacerbations in AERIFY-1, but AERIFY-2 showed non-significant 12.4% and 1.6% reductions. The trial inconsistency and 17–18% severe adverse event rates could complicate FDA approval prospects.
| Metric | Value |
|---|---|
| Price | $44.50 |
| Market Cap | $104.32B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 2.42% |
| 52-Week High | $60.12 |
| 52-Week Low | $42.33 |
| Volume | 2.60M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover SNY: 0 strong buy, 0 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $53.00.